Search

Your search keyword '"Burchell, Ann N."' showing total 675 results
Start Over Author "Burchell, Ann N."
675 results on '"Burchell, Ann N."'

1. Understanding COVID-19 Vaccine Confidence in People Living with HIV: A pan-Canadian Survey

Author

Costiniuk, Cecilia T., Singer, Joel, Needham, Judy, Yang, Yanbo, Qian, Hong, Chambers, Catharine, Burchell, Ann N., Samji, Hasina, Colmegna, Ines, del Canto, Sugandhi, Godin, Guy-Henri, Habanyama, Muluba, Hui, Christian, Kroch, Abigail, Mandarino, Enrico, Margolese, Shari, Martin, Carrie, Owino, Maureen, Mohammadi, Tima, Zhang, Wei, Pelaez, Sandra, Kovacs, Colin, Benko, Erika, Vulesevic, Branka, Cooper, Curtis L., and Anis, Aslam H.

Published
2023
Full Text
View/download PDF

4. Antibody neutralization capacity after COVID-19 vaccination in people with HIV (CIHR Canadian HIV trials network 328)

Author

Costiniuk, Cecilia T., Singer, Joel, Lee, Terry, Galipeau, Yannick, McCluskie, Pauline S., Arnold, Corey, Langlois, Marc-André, Needham, Judy, Jenabian, Mohammad-Ali, Burchell, Ann N., Samji, Hasina, Chambers, Catharine, Walmsley, Sharon, Ostrowski, Mario, Kovacs, Colin, Tan, Darrell H.S., Harris, Marianne, Hull, Mark, Brumme, Zabrina L., Lapointe, Hope R., Brockman, Mark A., Margolese, Shari, Mandarino, Enrico, Samarani, Suzanne, Vulesevic, Branka, Lebouche, Bertrand, Angel, Jonathan B., Routy, Jean-Pierre, Cooper, Curtis L., and Anis, Aslam H.

Published
2023
Full Text
View/download PDF

6. Associations of CD4 cell count measures with infection-related and infection-unrelated cancer risk among people with HIV

Author

Nicolau, Ioana A., primary, Moineddin, Rahim, additional, Brooks, Jennifer D., additional, Antoniou, Tony, additional, Gillis, Jennifer L., additional, Kendall, Claire E., additional, Cooper, Curtis, additional, Cotterchio, Michelle, additional, Salters, Kate, additional, Smieja, Marek, additional, Kroch, Abigail E., additional, Price, Colleen, additional, Mohamed, Anthony, additional, and Burchell, Ann N., additional

Published
2024
Full Text
View/download PDF

8. COVID‐19 vaccine effectiveness by HIV status and history of injection drug use: a test‐negative analysis

Author

Puyat, Joseph H., Wilton, James, Fowokan, Adeleke, Janjua, Naveed Zafar, Wong, Jason, Grennan, Troy, Chambers, Catharine, Kroch, Abigail, Costiniuk, Cecilia T., Cooper, Curtis L., Lauscher, Darren, Strong, Monte, Burchell, Ann N., Anis, Aslam, and Samji, Hasina

Subjects
Immune response -- Observations, Intravenous drug abuse -- Physiological aspects, HIV infection -- Physiological aspects, Health
Abstract

: Introduction: People living with HIV (PLWH) and/or who inject drugs may experience lower vaccine effectiveness (VE) against SARS‐CoV‐2 infection. Methods: A validated algorithm was applied to population‐based, linked administrative datasets in the British Columbia COVID‐19 Cohort (BCC19C) to ascertain HIV status and create a population of PLWH and matched HIV‐negative individuals. The study population was limited to individuals who received an RT‐PCR laboratory test for SARS‐CoV‐2 between 15 December 2020 and 21 November 2021 in BC, Canada. Any history of injection drug use (IDU) was ascertained using a validated administrative algorithm. We used a test‐negative study design (modified case−control analysis) and multivariable logistic regression to estimate adjusted VE by HIV status and history of IDU. Results: Our analysis included 2700 PLWH and a matched population of 375,043 HIV‐negative individuals, among whom there were 351 and 103,049 SARS‐CoV‐2 cases, respectively. The proportion of people with IDU history was much higher among PLWH compared to HIV‐negative individuals (40.7% vs. 4.3%). Overall VE during the first 6 months after second dose was lower among PLWH with IDU history (65.8%, 95% CI = 43.5–79.3) than PLWH with no IDU history (80.3%, 95% CI = 62.7–89.6), and VE was particularly low at 4–6 months (42.4%, 95% CI = −17.8 to 71.8 with IDU history vs. 64.0%; 95% CI = 15.7–84.7 without), although confidence intervals were wide. In contrast, overall VE was 88.6% (95% CI = 88.2–89.0) in the matched HIV‐negative population with no history of IDU and remained relatively high at 4–6 months after second dose (84.6%, 95% CI = 83.8–85.4). Despite different patterns of vaccine protection by HIV status and IDU history, peak estimates were similar (≥88%) across all populations. Conclusions: PLWH with a history of IDU may experience lower VE against COVID‐19 infection, although findings were limited by a small sample size. The lower VE at 4–6 months may have implications for booster dose prioritization for PLWH and people who inject drugs. The immunocompromising effect of HIV, substance use and/or co‐occurring comorbidities may partly explain these findings., INTRODUCTION People living with HIV (PLWH) and people who inject drugs (PWID) are two populations that often overlap and may experience lower vaccine effectiveness (VE) against COVID‐19 infection. Injection drug [...]

Published
2023
Full Text
View/download PDF

9. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Author

Costiniuk, Cecilia T., Singer, Joel, Lee, Terry, Galipeau, Yannick, McCluskie, Pauline S., Arnold, Corey, Langlois, Marc-André, Needham, Judy, Jenabian, Mohammad-Ali, Burchell, Ann N., Samji, Hasina, Chambers, Catharine, Walmsley, Sharon, Ostrowski, Mario, Kovacs, Colin, Tan, Darrell H.S., Harris, Marianne, Hull, Mark, Brumme, Zabrina L., Lapointe, Hope R., Brockman, Mark A., Margolese, Shari, Mandarino, Enrico, Samarani, Suzanne, Vulesevic, Branka, Lebouché, Bertrand, Angel, Jonathan B., Routy, Jean-Pierre, Cooper, Curtis L., and Anis, Aslam H.

Published
2023
Full Text
View/download PDF

15. Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study

Author

Costiniuk, Cecilia T., primary, Lee, Terry, additional, Singer, Joel, additional, Galipeau, Yannick, additional, Arnold, Corey, additional, Langlois, Marc-André, additional, Needham, Judy, additional, Jenabian, Mohammad-Ali, additional, Burchell, Ann N., additional, Samji, Hasina, additional, Chambers, Catharine, additional, Walmsley, Sharon, additional, Ostrowski, Mario, additional, Kovacs, Colin, additional, Tan, Darrell H. S., additional, Harris, Marianne, additional, Hull, Mark, additional, Brumme, Zabrina L., additional, Lapointe, Hope R., additional, Brockman, Mark A., additional, Margolese, Shari, additional, Mandarino, Enrico, additional, Samarani, Suzanne, additional, Lebouché, Bertrand, additional, Angel, Jonathan B., additional, Routy, Jean-Pierre, additional, Cooper, Curtis L., additional, and Anis, Aslam H., additional

Published
2024
Full Text
View/download PDF

16. Self-reported Human Papillomavirus Vaccination and Vaccine Effectiveness Among Men Who Have Sex with Men: A Quantitative Bias Analysis

Author

Chambers, Catharine, primary, Deeks, Shelley L., primary, Sutradhar, Rinku, primary, Cox, Joseph, primary, De Pokomandy, Alexandra, primary, Grennan, Troy, primary, Hart, Trevor, primary, Lambert, Gilles, primary, Moore, David M., primary, Grace, Daniel, primary, Grewal, Ramandip, primary, Jollimore, Jody, primary, Lachowsky, Nathan J., primary, Mah, Ashley, primary, Nisenbaum, Rosane, primary, Ogilvie, Gina, primary, Sauvageau, Chantal, primary, Tan, Darrell H.S., primary, Yeung, Anna, primary, and Burchell, Ann N., primary

Published
2024
Full Text
View/download PDF

21. Previous Syphilis Not Associated with Neurocognitive Outcomes in People Living with HIV in Ontario, Canada

Author

CHRISTENSEN, Brandon L., Tavangar, Farideh, Kroch, Abigail E., Burchell, Ann N., Rourke, Sean B., Rousseau, Rodney K., Raboud, Janet M., Bekele, Tsegaye, Tan, Darrell H.S., Kroch, Abigail, Burchell, Ann, Cohen, Jeffrey, Cooper, Curtis, Arbess, Gordon, Lavoie, Elizabeth, Loutfy, Mona, Andany, Nisha, Walmsley, Sharon, Silverman, Michael, Borque, Tammy, El-Helou, Phillipe, Gauvin, Holly, Tharao, Wangari, Li, Alan, Craig, Jeffrey, Martinez-Cajas, Jorge, Cotnam, Jasmine, Di Pede, Tony, Adam, Barry, Santibañez, Viviana, Rousseau, Rodney, Ndung’u, Mary, Chen, YiYi, Cameron, Ruth, Brophy, Jason, Bowerman, Aaron, Record, Dane, Muchano, Elisio, Grey, Cornel, Cotnam, Jasmine, Jackson, Randy, Young, Meghan, Stratton, Trevor, Rueda, Sergio, Burchell, Ann, Adam, Barry, Brennan, David, Cooper, Curtis, Hart, Trevor, Betts, Adrian, Loutfy, Mona, O’Brien, Kelly, Mbuagbaw, Lawrence, Giguere, Pierre, Benoit, Anita, Hillier, Sean, Nyambi, Agatha, Light, Lucia, Qureshi, Nahid, Bekele, Tsegaye, Kesler, Maya, Colyer, Sean, O’Brien, Kristen, Obioha, Adanna, Prabhu, Namita, and Groves, Maxwell

Published
2022
Full Text
View/download PDF

23. Sex Differences in Covid-19 Vaccine Confidence in People Living with HIV in Canada

Author

Vulesevic, Branka, primary, Lu, Jessica, additional, Burchell, Ann N., additional, Singer, Joel, additional, Needham, Judy, additional, Yang, Yanbo, additional, Qian, Hong, additional, Chambers, Catharine, additional, Samji, Hasina, additional, Colmegna, Ines, additional, del Canto, Sugandhi, additional, Godin, Guy-Henri, additional, Habanyama, Muluba, additional, Hui, Sze Shing Christian, additional, Kroch, Abigail, additional, Mandarino, Enrico, additional, Margolese, Shari, additional, Martin, Carrie, additional, Owino, Maureen, additional, Lau, Elisa, additional, Mohammadi, Tima, additional, Zhang, Wei, additional, Pelaez, Sandra, additional, Kovacs, Colin, additional, Benko, Erika, additional, Cooper, Curtis, additional, Anis, Aslam H., additional, and Costiniuk, Cecilia T., additional

Published
2024
Full Text
View/download PDF

27. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras

Author

Klein, Marina B, Althoff, Keri N, Jing, Yuezhou, Lau, Bryan, Kitahata, Mari, Re, Vincent Lo, Kirk, Gregory D, Hull, Mark, Kim, H Nina, Sebastiani, Giada, Moodie, Erica EM, Silverberg, Michael J, Sterling, Timothy R, Thorne, Jennifer E, Cescon, Angela, Napravnik, Sonia, Eron, Joe, Gill, M John, Justice, Amy, Peters, Marion G, Goedert, James J, Mayor, Angel, Thio, Chloe L, Cachay, Edward R, Moore, Richard, Research and Design of IeDEA, for the North American AIDS Cohort Collaboration on, Benson, Constance A, Bosch, Ronald J, Boswell, Stephen, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Samji, Hasina, Brooks, John T, Buchacz, Kate, Gebo, Kelly A, Moore, Richard D, Rodriguez, Benigno, Horberg, Michael A, Jacobsonc, Lisa P, D'Souza, Gypsyamber, Rourke, Sean B, Burchell, Ann N, Rachlis, Anita R, Hunter-Mellado, Robert F, Mayor, Angel M, Deeks, Steven G, Martin, Jeffrey N, Patel, Pragna, Saag, Michael S, Mugavero, Michael J, Willig, James, Eron, Joseph J, Kitahata, Mari M, Crane, Heidi M, Drozd, Daniel R, Haas, David, Bebawy, Sally, Turner, Megan, Justice, Amy C, Dubrow, Robert, Fiellin, David, Gange, Stephen J, Anastos, Kathryn, McKaig, Rosemary G, Freeman, Aimee M, Lent, Carol, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, and Abraham, Alison G

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Hepatitis, Emerging Infectious Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis - C, Digestive Diseases, Liver Disease, Hepatitis - B, Sexually Transmitted Infections, Infectious Diseases, HIV/AIDS, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, Aged, Alcohol Drinking, Anti-HIV Agents, Canada, Cohort Studies, Coinfection, End Stage Liver Disease, Female, HIV Infections, Hepatitis B, Hepatitis C, Humans, Incidence, Male, Middle Aged, Risk Factors, United States, HIV, hepatitis C virus, hepatitis B virus, coinfection, end-stage liver disease, North American AIDS Cohort Collaboration on Research and Design of IeDEA, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundHuman immunodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses are at increased risk of end-stage liver disease (ESLD). Whether modern antiretroviral therapy has reduced ESLD risk is unknown.MethodsTwelve clinical cohorts in the United States and Canada participating in the North American AIDS Cohort Collaboration on Research and Design validated ESLD events from 1996 to 2010. ESLD incidence rates and rate ratios according to hepatitis status adjusted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNA were estimated in calendar periods corresponding to major changes in antiretroviral therapy: early (1996-2000), middle (2001-2005), and modern (2006-2010) eras.ResultsAmong 34 119 HIV-infected adults followed for 129 818 person-years, 380 incident ESLD outcomes occurred. ESLD incidence (per 1000 person-years) was highest in triply infected (11.57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients. Adjusted incidence rate ratios (95% confidence intervals) comparing the modern to the early antiretroviral era were 0.95 (.61-1.47) for HCV, 0.95 (.40-2.26) for HBV, and 1.52 (.46-5.02) for triply infected patients. Use of antiretrovirals dually activity against HBV increased over time. However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir. There was little use of HCV therapy.ConclusionsDespite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years. Treatment with direct-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients.

Published
2016

28. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010

Author

Buchacz, Kate, Lau, Bryan, Jing, Yuezhou, Bosch, Ronald, Abraham, Alison G, Gill, M John, Silverberg, Michael J, Goedert, James J, Sterling, Timothy R, Althoff, Keri N, Martin, Jeffrey N, Burkholder, Greer, Gandhi, Neel, Samji, Hasina, Patel, Pragna, Rachlis, Anita, Thorne, Jennifer E, Napravnik, Sonia, Henry, Keith, Mayor, Angel, Gebo, Kelly, Gange, Stephen J, Moore, Richard D, Brooks, John T, Research and Design of IeDEA, for the North American AIDS Cohort Collaboration on, Kirk, Gregory D, Benson, Constance A, Bosch, Ronald J, Boswell, Stephen, Mayer, Kenneth H, Grasso, Chris, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Cescon, Angela, Gebo, Kelly A, Carey, John T, Rodriguez, Benigno, Horberg, Michael A, Jacobson, Lisa P, D'Souza, Gypsyamber, Klein, Marina B, Rourke, Sean B, Burchell, Ann N, Rachlis, Anita R, Hunter-Mellado, Robert F, Mayor, Angel M, Deeks, Steven G, Saag, Michael S, Mugavero, Michael J, Willig, James, Eron, Joseph J, Kitahata, Mari M, Crane, Heidi M, Drozd, Daniel R, Rebeiro, Peter F, Haas, David, Bebawy, Sally, Turner, Megan, Justice, Amy C, Dubrow, Robert, Fiellin, David, and Anastos, Kathryn

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Sexually Transmitted Infections, Infectious Diseases, Clinical Research, HIV/AIDS, Infection, AIDS-Related Opportunistic Infections, Adult, Canada, Cohort Studies, Female, Humans, Incidence, Male, Middle Aged, Survival Analysis, United States, AIDS-related opportunistic infections, HIV cohort studies, incidence, prophylaxis, combination antiretroviral therapy, CD4(+) T-lymphocyte count, epidemiology, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, CD4+ T-lymphocyte count, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundThere are few recent data on the rates of AIDS-defining opportunistic infections (OIs) among human immunodeficiency virus (HIV)-infected patients in care in the United States and Canada.MethodsWe studied HIV-infected participants in 16 cohorts in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) during 2000-2010. After excluding 16 737 (21%) with any AIDS-defining clinical events documented before NA-ACCORD enrollment, we analyzed incident OIs among the remaining 63 541 persons, most of whom received antiretroviral therapy during the observation. We calculated incidence rates per 100 person-years of observation (hereafter, "person-years") with 95% confidence intervals (CIs) for the first occurrence of any OI and select individual OIs during 2000-2003, 2004-2007, and 2008-2010.ResultsA total of 63 541 persons contributed 261 573 person-years, of whom 5836 (9%) developed at least 1 OI. The incidence rate of any first OI decreased over the 3 observation periods, with 3.0 cases, 2.4 cases, and 1.5 cases per 100 person-years of observation during 2000-2003, 2004-2007, and 2008-2010, respectively (Ptrend

Published
2016

30. An evaluation of an employment assistance program focused on people living with HIV in Toronto, Canada.

Author

Perri, Melissa, Hapsari, Ayu Pinky, Craig-Neil, Amy, Ho, Julia, Cattaneo, Jessica, Gaspar, Mark, Hunter, Charlotte, Rueda, Sergio, Burchell, Ann N., and Pinto, Andrew D.

Subjects
SOCIAL determinants of health, HUMAN services programs, RESEARCH funding, EVALUATION of human services programs, UNEMPLOYMENT, INTERVIEWING, QUANTITATIVE research, DESCRIPTIVE statistics, HIV infections, PSYCHOLOGY of HIV-positive persons, RESEARCH methodology, SOCIAL support, COMPARATIVE studies, EMPLOYMENT, COMMUNITY-based social services, SOCIAL problems
Abstract

Unemployment is more common among people living with HIV (PLWH) compared to the general population. PLWH who are employed have better physical and mental health outcomes compared to unemployed PLWH. The main objective of this mixed-methods study was to conduct a program evaluation of Employment Action (EACT), a community-based program that assists PLWH in Toronto, Ontario, Canada to maintain meaningful employment. We extracted quantitative data from two HIV services databases used by EACT, and collected qualitative data from 12 individuals who had been placed into paid employment through EACT. From 131 clients included in the analysis, 38.1% (n = 50) maintained their job for at least 6 weeks within the first year of enrollment in the EACT program. Gender, ethnicity, age, and first language did not predict employment maintenance. Our interviews highlighted the barriers and facilitators to effective service delivery. Key recommendations include implementing skills training, embedding PLWH as EACT staff, and following up with clients once they gain employment. Investment in social programs such as EACT are essential for strengthening their data collection capacity, active outreach to service users, and sufficient planning for the evaluation phase prior to program implementation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Detection and Clearance of Type-Specific and Phylogenetically Related Genital Human Papillomavirus Infections in Young Women in New Heterosexual Relationships.

Author

Arthur, Andrew W, El-Zein, Mariam, Burchell, Ann N, Tellier, Pierre-Paul, Coutlée, François, and Franco, Eduardo L

Abstract

Background Understanding the natural history of human papillomavirus (HPV) infections is essential to cervical cancer prevention planning. We estimated HPV type-specific infection detection and clearance in young women. Methods The HPV Infection and Transmission among Couples through Heterosexual activity (HITCH) study is a prospective cohort of 502 college-age women who recently initiated a heterosexual relationship. We tested vaginal samples collected at 6 clinical visits over 24 months for 36 HPV types. Using rates and Kaplan-Meier analysis, we estimated time-to-event statistics with 95% confidence intervals (CIs) for detection of incident infections and clearance of incident and present-at-baseline infections (separately). We conducted analyses at the woman- and HPV-levels, with HPV types grouped by phylogenetic relatedness. Results By 24 months, we detected incident infections in 40.4% (CI, 33.4%–48.4%) of women. Incident subgenus 1 (43.4; CI, 33.6–56.4), 2 (47.1; CI, 39.9–55.5), and 3 (46.6; CI, 37.7–57.7) infections cleared at similar rates per 1000 infection-months. We observed similar homogeny in HPV-level clearance rates among present-at-baseline infections. Conclusions Our analyses provide type-specific infection natural history estimates for cervical cancer prevention planning. HPV-level analyses did not clearly indicate that high oncogenic risk subgenus 2 infections persist longer than their low oncogenic risk subgenera 1 and 3 counterparts. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Trends in infection-related and infection-unrelated cancer incidence among people with and without HIV infection in Ontario, Canada, 1996–2020: a population-based matched cohort study using health administrative data

Author

Nicolau, Ioana A., primary, Moineddin, Rahim, additional, Antoniou, Tony, additional, Brooks, Jennifer D., additional, Gillis, Jennifer L., additional, Kendall, Claire E., additional, Cooper, Curtis, additional, Cotterchio, Michelle, additional, Salters, Kate, additional, Smieja, Marek, additional, Kroch, Abigail E., additional, Lindsay, Joanne D., additional, Price, Colleen, additional, Mohamed, Anthony, additional, and Burchell, Ann N., additional

Published
2023
Full Text
View/download PDF

39. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.

Author

Silverberg, Michael J, Lau, Bryan, Achenbach, Chad J, Jing, Yuezhou, Althoff, Keri N, D'Souza, Gypsyamber, Engels, Eric A, Hessol, Nancy A, Brooks, John T, Burchell, Ann N, Gill, M John, Goedert, James J, Hogg, Robert, Horberg, Michael A, Kirk, Gregory D, Kitahata, Mari M, Korthuis, Philip T, Mathews, William C, Mayor, Angel, Modur, Sharada P, Napravnik, Sonia, Novak, Richard M, Patel, Pragna, Rachlis, Anita R, Sterling, Timothy R, Willig, James H, Justice, Amy C, Moore, Richard D, Dubrow, Robert, and North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS

Subjects
North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, Humans, Sarcoma, Kaposi, HIV Infections, Neoplasms, Lymphoma, Non-Hodgkin, Colorectal Neoplasms, Anus Neoplasms, Liver Neoplasms, Lung Neoplasms, Incidence, Proportional Hazards Models, Cohort Studies, Comorbidity, Age Distribution, Adult, Aged, Middle Aged, North America, Female, Male, Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundCancer is increasingly common among persons with HIV.ObjectiveTo examine calendar trends in cumulative cancer incidence and hazard rate by HIV status.DesignCohort study.SettingNorth American AIDS Cohort Collaboration on Research and Design during 1996 to 2009.Participants86 620 persons with HIV and 196 987 uninfected adults.MeasurementsCancer type-specific cumulative incidence by age 75 years and calendar trends in cumulative incidence and hazard rates, each by HIV status.ResultsCumulative incidences of cancer by age 75 years for persons with and without HIV, respectively, were as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% and 2.8%; anal cancer, 1.5% and 0.05%; colorectal cancer, 1.0% and 1.5%; liver cancer, 1.1% and 0.4%; Hodgkin lymphoma, 0.9% and 0.09%; melanoma, 0.5% and 0.6%; and oral cavity/pharyngeal cancer, 0.8% and 0.8%. Among persons with HIV, calendar trends in cumulative incidence and hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma. For anal, colorectal, and liver cancer, increasing cumulative incidence, but not hazard rate trends, were due to the decreasing mortality rate trend (-9% per year), allowing greater opportunity to be diagnosed. Despite decreasing hazard rate trends for lung cancer, Hodgkin lymphoma, and melanoma, cumulative incidence trends were not seen because of the compensating effect of the declining mortality rate.LimitationSecular trends in screening, smoking, and viral co-infections were not evaluated.ConclusionCumulative cancer incidence by age 75 years, approximating lifetime risk in persons with HIV, may have clinical utility in this population. The high cumulative incidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and sustained antiretroviral therapy and smoking cessation.

Published
2015

45. Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators

Author

Althoff, Keri N, Rebeiro, Peter, Brooks, John T, Buchacz, Kate, Gebo, Kelly, Martin, Jeffrey, Hogg, Robert, Thorne, Jennifer E, Klein, Marina, Gill, M John, Sterling, Timothy R, Yehia, Baligh, Silverberg, Michael J, Crane, Heidi, Justice, Amy C, Gange, Stephen J, Moore, Richard, Kitahata, Mari M, Horberg, Michael A, Research and Design, for the North American AIDS Cohort Collaboration on, Kirk, Gregory D, Benson, Constance A, Bosch, Ronald J, Collier, Ann C, Boswell, Stephen, Grasso, Chris, Mayer, Kenneth H, Hogg, Robert S, Harrigan, P Richard, Montaner, Julio SG, Cescon, Angela, Samji, Hasina, Gebo, Kelly A, Moore, Richard D, Carey, John T, Goedert, James J, Jacobson, Lisa P, Klein, Marina B, Rourke, Sean B, Burchell, Ann N, Rachlis, Anita R, Hunter-Mellado, Robert F, Mayor, Angel M, Deeks, Steven G, Martin, Jeffrey N, Saag, Michael S, Mugavero, Michael J, Willig, James, Eron, Joseph J, Napravnik, Sonia, Crane, Heidi M, Dubrow, Robert, Fiellin, David, Haas, David, Bebawy, Sally, Turner, Megan, Anastos, Kathryn, McKaig, Rosemary G, Freeman, Aimee M, Lent, Carol, Van Rompaey, Stephen E, Morton, Liz, McReynolds, Justin, Lober, William B, Abraham, Alison G, Lau, Bryan, Zhang, Jinbing, Jing, Jerry, Golub, Elizabeth, Modur, Shari, Hanna, David B, Wong, Cherise, and Mendes, Adell

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Infectious Diseases, Behavioral and Social Science, Prevention, Sexually Transmitted Infections, Health Services, Women's Health, HIV/AIDS, Clinical Research, Infection, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Anti-Retroviral Agents, Cohort Studies, Continuity of Patient Care, Cross-Sectional Studies, Female, HIV Infections, Healthcare Disparities, Humans, Male, Middle Aged, United States, United States Dept. of Health and Human Services, Viral Load, HIV, quality of care, retention in care, antiretroviral therapy, HIV RNA suppression, North American AIDS Cohort Collaboration on Research and Design, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

We estimated US Department of Health and Human Services (DHHS)-approved human immunodeficiency virus (HIV) indicators. Among patients, 71% were retained in care, 82% were prescribed treatment, and 78% had HIV RNA ≤200 copies/mL; younger adults, women, blacks, and injection drug users had poorer outcomes. Interventions are needed to reduce retention- and treatment-related disparities.

Published
2014

46. Serologic response to human papillomavirus genotypes following vaccination: findings from the HITCH cohort study.

Author

Morais, Samantha, Wissing, Michel D., Khosrow-Khavar, Farzin, Burchell, Ann N., Tellier, Pierre-Paul, Coutlée, François, Waterboer, Tim, El-Zein, Mariam, and Franco, Eduardo L.

Subjects
HUMAN papillomavirus, PEARSON correlation (Statistics), HUMORAL immunity, CHIMERIC proteins, VACCINATION
Abstract

Human papillomavirus (HPV) infection contributes to approximately 5% of the worldwide cancer burden. The three-dose HPV vaccine has demonstrated immunogenicity and efficacy. Humoral responses may be critical for preventing, controlling, and/or eliminating HPV infection. Using data from the HITCH cohort, we analysed humoral immune response to HPV vaccination among women in relation to the phylogenetic relatedness of HPV genotypes. We included 96 women aged 18–24 years attending college or university in Montreal, Canada. Participants provided blood samples at enrolment and five follow-up visits. Antibody response to bacterially expressed L1 and E6 glutathione S‐transferase fusion proteins of multiple Alphapapillomavirus types, and to virus-like particles (VLP-L1) of HPV16 and HPV18 were measured using multiplex serology. We assessed correlations between antibody seroreactivities using Pearson correlations (r). At enrolment, 87.7% of participants were unvaccinated, 2.4% had received one, 3.2% two, and 6.7% three doses of HPV vaccine. The corresponding L1 seropositivity to any HPV was 41.2%, 83.3%, 100%, and 97.0%. Between-type correlations for L1 seroreactivities increased with the number of vaccine doses, from one to three. Among the latter, the strongest correlations were observed for HPV58–HPV33 (Pearson correlation [r] = 0.96; α9-species); HPV11–HPV6 (r = 0.96; α10-species); HPV45–HPV18 (r = 0.95; α7-species), and HPV68–HPV59 (r = 0.95; α7-species). Correlations between HPV-specific antibody seroreactivities are affected by phylogenetic relatedness, with anti-L1 correlations becoming stronger with the number of vaccine doses received. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. Community and Health Care Provider Preferences for Bacterial Sexually Transmitted Infection Testing Interventions for Gay, Bisexual, and Other Men Who Have Sex With Men: e-Delphi Study

Author

Yeung, Anna, primary, Lisk, Ryan, additional, Rana, Jayoti, additional, Guiang, Charlie B, additional, Bacon, Jean, additional, Brunetta, Jason, additional, Gilbert, Mark, additional, Gesink, Dionne, additional, Grewal, Ramandip, additional, Kwag, Michael, additional, Logie, Carmen H, additional, Mitterni, Leo, additional, Shahin, Rita, additional, Tan, Darrell HS, additional, and Burchell, Ann N, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results